A detailed history of Franklin Resources Inc transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Franklin Resources Inc holds 941,570 shares of MIRM stock, worth $38 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
941,570
Previous 941,374 0.02%
Holding current value
$38 Million
Previous $23.6 Million 36.14%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$23.57 - $34.85 $4,619 - $6,830
196 Added 0.02%
941,570 $32.2 Million
Q1 2024

May 13, 2024

BUY
$24.92 - $30.02 $705,385 - $849,746
28,306 Added 3.1%
941,374 $23.6 Million
Q4 2023

Feb 09, 2024

BUY
$27.14 - $34.93 $4.57 Million - $5.88 Million
168,446 Added 22.62%
913,068 $27 Million
Q3 2023

Nov 13, 2023

BUY
$24.63 - $32.85 $3.29 Million - $4.39 Million
133,541 Added 21.85%
744,622 $23.5 Million
Q2 2023

Aug 11, 2023

BUY
$23.51 - $30.09 $4.95 Million - $6.34 Million
210,579 Added 52.58%
611,081 $15.8 Million
Q1 2023

May 12, 2023

BUY
$19.19 - $24.1 $383 - $482
20 Added 0.0%
400,502 $9.62 Million
Q4 2022

Feb 10, 2023

SELL
$17.59 - $23.83 $20 Million - $27.1 Million
-1,135,642 Reduced 73.93%
400,482 $7.81 Million
Q3 2022

Nov 14, 2022

BUY
$19.98 - $29.44 $5.73 Million - $8.45 Million
287,002 Added 22.98%
1,536,124 $32.3 Million
Q2 2022

Aug 11, 2022

BUY
$18.42 - $27.5 $10,646 - $15,895
578 Added 0.05%
1,249,122 $24.3 Million
Q1 2022

May 13, 2022

BUY
$15.5 - $23.93 $11.8 Million - $18.3 Million
764,441 Added 157.91%
1,248,544 $27.5 Million
Q4 2021

Feb 11, 2022

BUY
$13.05 - $19.35 $6.32 Million - $9.37 Million
484,103 New
484,103 $7.72 Million

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.48B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track This Portfolio

Track Franklin Resources Inc Portfolio

Follow Franklin Resources Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.